NexImmune, Inc.

NexImmune, Inc. (NEXI) priced its initial public offering on Feb 16, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $110M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $366.4M. Barclays was lead-left underwriter, joined by Cantor, Raymond James and Allen & Company. Mintz advised the company and Cooley advised the underwriters.

NexImmune, Inc. is a clinical-stage biotechnology company developing immunotherapy that directs the body's own T cells using its Artificial Immune Modulation nanoparticle platform, which acts as synthetic dendritic cells. Its two candidates in human trials are NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma.

Status

IPO

Ticker

NEXI

Exchange

Nasdaq Global Market

Priced

Feb 16, 2021

IPO price

$17.00

Price range

$15.00–$17.00

Raised

$110M

Market cap at IPO price

$366.4M

First filed

Jan 19, 2021

Underwriters

Barclays, Cantor, Raymond James and Allen & Company

Company counsel

Mintz

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MD

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.